# Diabetes Research Hub — Monitor Report

**Run date:** 2026-06-10 (automated monitor)
**Scope:** Review of latest script outputs in `Analysis/Results/`, snapshot comparison, and a web check for breaking news.
**Mode:** Read-only review. No existing files modified.

---

## Executive Summary

Quiet day on the data side: zero clinical-trial changes day-over-day, and PubMed churned 64 papers in / 64 out with **7 cross-domain papers** worth a look. The real signal this week is **external**: Eli Lilly's **retatrutide** reported its first-ever Phase 3 results in T2D + obesity at the **ADA 2026 Scientific Sessions (June 6)** — a first-in-class triple-hormone (GIP/GLP-1/glucagon) agonist. The hub's PubMed and trial data both already track retatrutide, so this is a prompt to curate, not to re-collect.

One housekeeping item: **`literature_gap_data.json` is ~51 days old** (Apr 20). The interpreted report was regenerated June 9, but the underlying gap dataset has not been refreshed.

---

## File System Status

All four expected core outputs are present and the two API-driven feeds are fresh (generated 2026-06-10 07:04–07:05):

| File | Last modified | Status |
|------|---------------|--------|
| `hub_monitor_report.md` | 2026-06-10 07:05 | Fresh |
| `clinical_trials_latest.json` | 2026-06-10 07:04 | Fresh (806 trials) |
| `clinical_trials_summary.md` | 2026-06-10 07:04 | Fresh |
| `pubmed_recent_latest.json` | 2026-06-10 07:05 | Fresh (167 papers) |
| `pubmed_recent_summary.md` | 2026-06-10 07:05 | Fresh |
| `literature_gap_report.md` | 2026-06-09 19:30 | Recent |
| `literature_gap_data.json` | 2026-04-20 15:35 | **STALE (~51 days)** |

The hub monitor also flags **699 result files older than 14 days** — mostly the dated snapshot archive, which is expected. The only stale file that materially affects this review is the gap dataset above.

*(Note: `hub_monitor_report.md` lists its previous scan as 2026-06-09 19:25 and its hub root under a different session mount path — cosmetic, not a data issue.)*

---

## Clinical Trial Changes

**Day-over-day diff (2026-06-09 → 2026-06-10): no changes.** New trials: 0 · Removed: 0 · Status changes: 0 · New results posted: 0.

Snapshot totals: **806 unique trials** — 264 RECRUITING, 135 NOT_YET_RECRUITING, 108 ACTIVE_NOT_RECRUITING, 292 COMPLETED. 125 are Phase 3; **46 are Phase 3 + RECRUITING**.

### Key Phase 3 trials from priority organizations (status as of snapshot)

| NCT ID | Sponsor | Therapy / focus | Status |
|--------|---------|-----------------|--------|
| NCT06832410 | Vertex | VX-880 (zimislecel) — T1D islet cell therapy | RECRUITING |
| NCT04786262 | Vertex | VX-880 (zimislecel) — T1D islet cell therapy | RECRUITING |
| NCT05791201 | Vertex | VX-264 (encapsulated islets) — T1D | ACTIVE_NOT_RECRUITING |
| NCT07222332 | Eli Lilly | Baricitinib — preserve beta-cell function (T1D) | RECRUITING |
| NCT07222137 | Eli Lilly | Baricitinib — delay stage 3 T1D | RECRUITING |
| NCT06297603 / NCT05929079 / NCT06260722 | Eli Lilly | Retatrutide (vs placebo / vs semaglutide) | ACTIVE_NOT_RECRUITING |
| NCT06972472 / NCT06993792 | Eli Lilly | Orforglipron — T2D | ACTIVE_NOT_RECRUITING |
| NCT06534411 / NCT07282613 | Novo Nordisk | CagriSema — glycemic | ACTIVE / NOT_YET_RECRUITING |
| NCT07076199 / NCT07564414 | Novo Nordisk | Insulin icodec (weekly) | RECRUITING |

The two **Eli Lilly baricitinib Phase 3 T1D-prevention trials** (NCT07222332, NCT07222137) are the most strategically interesting newcomers to watch — JAK inhibition for beta-cell preservation is directly relevant to the T1D immunotherapy domain.

### Recently posted results (within ~7 days, worth a glance)

- **NCT05813912 (Novo Nordisk, 2026-06-03)** — weekly insulin icodec; aligns with the cross-domain icodec paper below.
- **NCT04965935 (UHN Toronto, 2026-06-08)** — SGLT2 inhibitor efficacy/mechanism/safety.
- **NCT04167761 (Stanford, 2026-06-04)** — ertugliflozin cardioprotective / epicardial fat.
- **NCT03696797 (Wake Forest, 2026-06-09)** — iron reduction for diabetes + NAFLD.

(No results posted by the priority sponsors in the last 7 days beyond the icodec entry above; ~80 trials show 2026 result postings overall.)

---

## PubMed Highlights

30-day lookback, 167 unique papers across 16 alert domains; domain coverage is even (~10 papers/domain). Day-range diff vs the 2026-06-07 snapshot: **64 new papers in, 64 out.**

### Cross-domain papers (highest priority — 7 new this cycle)

1. **[42259339]** Orforglipron vs dapagliflozin in T2D with inadequate glycaemic control — *T2D GLP-1 New × orforglipron × dapagliflozin*. Head-to-head oral GLP-1 vs SGLT2; directly relevant given the April orforglipron FDA approval.
2. **[42254168]** Once-weekly insulin icodec — clinical implications ("paradigm shift") — *T2D Remission × icodec*. Pairs with NCT05813912 results.
3. **[42261705]** Semaglutide showed limited improvement in Alzheimer's (revisiting EVOKE) — *T2D GLP-1 New × Biomarker*. Notable negative/limiting result.
4. **[42251923]** Gut microbiome-derived metabolites predicting bariatric surgery outcomes — *T2D Remission × Microbiome*.
5. **[42259341]** Mechanistic pathways of cardiometabolic multi-long-term-conditions — *Microbiome × Multi-Omics*.
6. **[42258064]** MNRS network-based ranking for critical transitions in complex disease — *Biomarker × Microbiome*. Methodology relevant to Tier 1 multi-omics work.
7. **[42262824]** Urine Aquaporin-5 as biomarker in diabetic nephropathy — *Biomarker × Complications*.

Also flagged from the full set: **[42251203]** plasma 3-miRNA signature (*Biomarker × Gene Therapy*) and **[42258750]** immune modeling of autologous vs allogeneic SC-islet grafts (T1D Stem Cell Cure) — both relevant to Tier 1 areas.

### Key-therapy mentions (title/abstract)

semaglutide 9 · icodec 4 · orforglipron 4 · CagriSema 4 · dapagliflozin 4 · teplizumab 3 · tirzepatide 2 · baricitinib 2 · retatrutide 1 · efsitora 1. Notable items: CagriSema efficacy/safety cluster ([42251856/859/860]), orforglipron + titrated insulin glargine ([42251769]), retatrutide GIP/GLP-1/glucagon efficacy & safety ([42250575]).

### Volume trend

Snapshot file sizes have grown steadily (~96 KB in mid-March → ~132 KB now), consistent with rising publication volume in tracked domains. No domain is anomalously silent this cycle.

---

## Gap Analysis Summary

From `literature_gap_report.md` (regenerated 2026-06-09; BRONZE validation — single analytical source, expert confirmation required). Top 5 "potentially meaningful" under-researched intersections (Gap Score 100, ~0 joint pubs):

1. **Beta Cell Regen × Health Equity** — who gets access to regenerative therapies; equity analysis absent.
2. **Insulin Resistance × Islet Transplant** — IR in transplant recipients affects graft survival; barely studied.
3. **Islet Transplant × Drug Repurposing** — repurposing immunosuppressants for islet protection; no computational screening.
4. **Islet Transplant × Health Equity** — access concentrated at select centers; equity research absent.
5. **Gene Therapy × LADA** — LADA's autoimmune mechanism as a gene-therapy candidate; no crossover.

### Alignment with Tier 1 contribution areas (RESEARCH_DOCTRINE.md)

These gaps map cleanly onto Tier 1 strengths:

- **Drug Repurposing (Tier 1 #4)** — gaps #3 (Islet Transplant × Drug Repurposing) plus the "Drug Repurposing × LADA / × Health Equity" pairs are directly actionable via network-pharmacology screening, which the hub already has tooling for (`islet_repurposing_*` outputs).
- **Literature Synthesis & Gap Analysis (Tier 1 #2)** — the whole gap-mapping exercise is squarely in-scope; several pairs (e.g., Islet Transplant × Insulin Resistance) are good candidates for a verification PubMed search to confirm the gap is real vs. a terminology artifact.
- **Multi-Omics Biomarker Integration (Tier 1 #1)** — the cross-domain Biomarker × Microbiome / Multi-Omics papers above are method-aligned and worth incorporating.

Caveat per doctrine: gap scores are BRONZE / keyword-based; confirm against Cochrane/PROSPERO before treating any intersection as a true white space.

---

## Breaking News (web check, last ~7 days)

- **Retatrutide Phase 3 (first results) — June 6, 2026, ADA Scientific Sessions, New Orleans.** First-in-class triple-hormone (GIP/GLP-1/glucagon) agonist showed positive outcomes in T2D + obesity, plus improvements in obstructive sleep apnea and knee-osteoarthritis pain. Significant: first triple-hormone therapy addressing T2D and obesity together. The hub already tracks retatrutide (trials NCT06297603/NCT05929079/NCT06260722; PubMed [42250575]) — **curate, don't re-collect.**
- **Orforglipron (Foundayo) — FDA approved early April 2026** for chronic weight management (first oral GLP-1 without food/water restrictions). Not new this week, but context for the orforglipron-heavy PubMed cycle. No new FDA diabetes action found in the last 7 days.
- **Zimislecel (VX-880):** no FDA approval news found this week; Vertex Phase 3 trials remain RECRUITING in the snapshot.

*Evidence note: web items above are NEWS-level (conference presentation / regulatory press), not peer-reviewed primary data — label accordingly if promoted into the tracker.*

---

## Recommended Actions

1. **Refresh the gap dataset** — `literature_gap_data.json` is ~51 days old. Run: `python project1_literature_gap_analysis.py`.
2. **Curate retatrutide ADA 2026 results** — add a row to `clinical_trials_summary.md` "Notable Trials to Watch" for the retatrutide Phase 3 program (NCT05929079 / NCT06260722) and log the ADA presentation as a NEWS-level evidence item; await peer-reviewed publication before raising evidence level.
3. **Review the 7 cross-domain papers**, prioritizing [42259339] (orforglipron vs dapagliflozin) and [42258064] (network-ranking method — Tier 1 multi-omics relevance).
4. **Add Lilly baricitinib T1D-prevention Phase 3 trials** (NCT07222332, NCT07222137) to the watch list — directly relevant to the T1D immunotherapy domain.
5. **Pursue a Tier 1 drug-repurposing gap** — gap #3 (Islet Transplant × Drug Repurposing) aligns with existing `islet_repurposing_*` tooling; run a PubMed verification search to confirm the gap before committing analysis time.
6. **No trigger to re-run** `baseline_clinical_trials.py` or `baseline_pubmed_alerts.py` — both feeds are current as of this morning.

---
*Generated by the automated Diabetes Research Hub monitor — 2026-06-10. Read-only review; no source files modified. Gap classifications are BRONZE (single-source) per Research Doctrine v1.0.*
